Back to search results
NCT06262451

Fecal Microbiota Transplant National Registry

Enrolling by Invitation
Not specifiedAll AgesObservational
University of California, San Francisco
~10 participants
Updated 2025-06-10 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To assess short-term and long-term safety of FMT and other gut-related-microbiota products
Measured over 10 years

Conditions

Fecal Microbiota Transplant

Explore related trials

Fecal Microbiota Transplantation

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Max Brondfield, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Ability to give informed consent
Receiving FMT or other gut-related microbiota product within 90 days after providing consent
Access to internet and/or telephone
Ability to give informed consent
Providing stool sample for FMT

Exclusion

Incarceration

What this trial measures

  • To assess short-term and long-term safety of FMT and other gut-related-microbiota products10 years

    The safety of FMT is currently the greatest concern related to its use, and characterizing the safety of FMT and subsequent gut-related-microbiota products is the primary goal of the Registry. Short-term adverse events relate primarily to the method of delivery (e.g. colonoscopy) and to acute infections or other AEs from the donor fecal material and should be readily definable and quantifiable.The human-to-human transfer of feces may be associated with long-term health risks to the recipient because the gut microbiota is composed of many components that have not been characterized and can change over time in ways that cannot be currently predicted. It is imperative to determine if FMT leads to unintended development of serious conditions due to the transfer of gut microbiota. In addition to infections, the possibility that gut microbiota associated with a disease phenotype will be transplanted and result in chronic disease in recipients must be assessed.